Cargando…

Clinical Practice Guidelines Using GRADE and AGREE II for the Impact of Genetic Variants on Plasma Lipid/Lipoprotein/Apolipoprotein Responsiveness to Omega-3 Fatty Acids

BACKGROUND: A recent systematic review, which used the GRADE methodology, concluded that there is strong evidence for two gene-diet associations related to omega-3 and plasma triglyceride (TG) responses. Systematic reviews can be used to inform the development of clinical practice guidelines (CPGs)....

Descripción completa

Detalles Bibliográficos
Autores principales: Keathley, Justine, Garneau, Véronique, Marcil, Valérie, Mutch, David M., Robitaille, Julie, Rudkowska, Iwona, Sofian, Gabriela, Desroches, Sophie, Vohl, Marie-Claude
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8883048/
https://www.ncbi.nlm.nih.gov/pubmed/35237638
http://dx.doi.org/10.3389/fnut.2021.768474
_version_ 1784659842313486336
author Keathley, Justine
Garneau, Véronique
Marcil, Valérie
Mutch, David M.
Robitaille, Julie
Rudkowska, Iwona
Sofian, Gabriela
Desroches, Sophie
Vohl, Marie-Claude
author_facet Keathley, Justine
Garneau, Véronique
Marcil, Valérie
Mutch, David M.
Robitaille, Julie
Rudkowska, Iwona
Sofian, Gabriela
Desroches, Sophie
Vohl, Marie-Claude
author_sort Keathley, Justine
collection PubMed
description BACKGROUND: A recent systematic review, which used the GRADE methodology, concluded that there is strong evidence for two gene-diet associations related to omega-3 and plasma triglyceride (TG) responses. Systematic reviews can be used to inform the development of clinical practice guidelines (CPGs). OBJECTIVE: To provide guidance for clinical practice related to genetic testing for evaluating responsiveness to dietary/supplemental omega-3s and their impact on plasma lipids/lipoproteins/apolipoproteins. DESIGN: Using the results of the abovementioned systematic review, the first CPGs in nutrigenetics were developed using the established GRADE methodology and AGREE II approach. RESULTS: Three clinical practice recommendations were developed. Most gene-diet associations identified in the literature lack adequate scientific and clinical validity to warrant consideration for implementing in a practice setting. However, two gene-diet associations with strong evidence (GRADE quality: moderate and high) can be considered for implementation into clinical practice in certain cases: male APOE-E4 carriers (rs429358, rs7412) and TG changes in response to the omega-3 fatty acids eicosapentaenoic acid (EPA) and/or docosahexaenoic acid (DHA) as well as a 31-SNP nutrigenetic risk score and TG changes in response to EPA+DHA among adults with overweight/obesity. Ethical and regulatory implications must be considered when providing APOE nutrigenetic tests given the well-established link between APOE genetic variation and Alzheimer's Disease. CONCLUSION: Most of the evidence in this area is not ready for implementation into clinical practice primarily due to low scientific validity (low quality of evidence). However, the first CPGs in nutrigenetics have been developed for two nutrigenetic associations with strong scientific validity, related to dietary/supplemental omega-3 and TG responses.
format Online
Article
Text
id pubmed-8883048
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-88830482022-03-01 Clinical Practice Guidelines Using GRADE and AGREE II for the Impact of Genetic Variants on Plasma Lipid/Lipoprotein/Apolipoprotein Responsiveness to Omega-3 Fatty Acids Keathley, Justine Garneau, Véronique Marcil, Valérie Mutch, David M. Robitaille, Julie Rudkowska, Iwona Sofian, Gabriela Desroches, Sophie Vohl, Marie-Claude Front Nutr Nutrition BACKGROUND: A recent systematic review, which used the GRADE methodology, concluded that there is strong evidence for two gene-diet associations related to omega-3 and plasma triglyceride (TG) responses. Systematic reviews can be used to inform the development of clinical practice guidelines (CPGs). OBJECTIVE: To provide guidance for clinical practice related to genetic testing for evaluating responsiveness to dietary/supplemental omega-3s and their impact on plasma lipids/lipoproteins/apolipoproteins. DESIGN: Using the results of the abovementioned systematic review, the first CPGs in nutrigenetics were developed using the established GRADE methodology and AGREE II approach. RESULTS: Three clinical practice recommendations were developed. Most gene-diet associations identified in the literature lack adequate scientific and clinical validity to warrant consideration for implementing in a practice setting. However, two gene-diet associations with strong evidence (GRADE quality: moderate and high) can be considered for implementation into clinical practice in certain cases: male APOE-E4 carriers (rs429358, rs7412) and TG changes in response to the omega-3 fatty acids eicosapentaenoic acid (EPA) and/or docosahexaenoic acid (DHA) as well as a 31-SNP nutrigenetic risk score and TG changes in response to EPA+DHA among adults with overweight/obesity. Ethical and regulatory implications must be considered when providing APOE nutrigenetic tests given the well-established link between APOE genetic variation and Alzheimer's Disease. CONCLUSION: Most of the evidence in this area is not ready for implementation into clinical practice primarily due to low scientific validity (low quality of evidence). However, the first CPGs in nutrigenetics have been developed for two nutrigenetic associations with strong scientific validity, related to dietary/supplemental omega-3 and TG responses. Frontiers Media S.A. 2022-02-14 /pmc/articles/PMC8883048/ /pubmed/35237638 http://dx.doi.org/10.3389/fnut.2021.768474 Text en Copyright © 2022 Keathley, Garneau, Marcil, Mutch, Robitaille, Rudkowska, Sofian, Desroches and Vohl. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Nutrition
Keathley, Justine
Garneau, Véronique
Marcil, Valérie
Mutch, David M.
Robitaille, Julie
Rudkowska, Iwona
Sofian, Gabriela
Desroches, Sophie
Vohl, Marie-Claude
Clinical Practice Guidelines Using GRADE and AGREE II for the Impact of Genetic Variants on Plasma Lipid/Lipoprotein/Apolipoprotein Responsiveness to Omega-3 Fatty Acids
title Clinical Practice Guidelines Using GRADE and AGREE II for the Impact of Genetic Variants on Plasma Lipid/Lipoprotein/Apolipoprotein Responsiveness to Omega-3 Fatty Acids
title_full Clinical Practice Guidelines Using GRADE and AGREE II for the Impact of Genetic Variants on Plasma Lipid/Lipoprotein/Apolipoprotein Responsiveness to Omega-3 Fatty Acids
title_fullStr Clinical Practice Guidelines Using GRADE and AGREE II for the Impact of Genetic Variants on Plasma Lipid/Lipoprotein/Apolipoprotein Responsiveness to Omega-3 Fatty Acids
title_full_unstemmed Clinical Practice Guidelines Using GRADE and AGREE II for the Impact of Genetic Variants on Plasma Lipid/Lipoprotein/Apolipoprotein Responsiveness to Omega-3 Fatty Acids
title_short Clinical Practice Guidelines Using GRADE and AGREE II for the Impact of Genetic Variants on Plasma Lipid/Lipoprotein/Apolipoprotein Responsiveness to Omega-3 Fatty Acids
title_sort clinical practice guidelines using grade and agree ii for the impact of genetic variants on plasma lipid/lipoprotein/apolipoprotein responsiveness to omega-3 fatty acids
topic Nutrition
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8883048/
https://www.ncbi.nlm.nih.gov/pubmed/35237638
http://dx.doi.org/10.3389/fnut.2021.768474
work_keys_str_mv AT keathleyjustine clinicalpracticeguidelinesusinggradeandagreeiifortheimpactofgeneticvariantsonplasmalipidlipoproteinapolipoproteinresponsivenesstoomega3fattyacids
AT garneauveronique clinicalpracticeguidelinesusinggradeandagreeiifortheimpactofgeneticvariantsonplasmalipidlipoproteinapolipoproteinresponsivenesstoomega3fattyacids
AT marcilvalerie clinicalpracticeguidelinesusinggradeandagreeiifortheimpactofgeneticvariantsonplasmalipidlipoproteinapolipoproteinresponsivenesstoomega3fattyacids
AT mutchdavidm clinicalpracticeguidelinesusinggradeandagreeiifortheimpactofgeneticvariantsonplasmalipidlipoproteinapolipoproteinresponsivenesstoomega3fattyacids
AT robitaillejulie clinicalpracticeguidelinesusinggradeandagreeiifortheimpactofgeneticvariantsonplasmalipidlipoproteinapolipoproteinresponsivenesstoomega3fattyacids
AT rudkowskaiwona clinicalpracticeguidelinesusinggradeandagreeiifortheimpactofgeneticvariantsonplasmalipidlipoproteinapolipoproteinresponsivenesstoomega3fattyacids
AT sofiangabriela clinicalpracticeguidelinesusinggradeandagreeiifortheimpactofgeneticvariantsonplasmalipidlipoproteinapolipoproteinresponsivenesstoomega3fattyacids
AT desrochessophie clinicalpracticeguidelinesusinggradeandagreeiifortheimpactofgeneticvariantsonplasmalipidlipoproteinapolipoproteinresponsivenesstoomega3fattyacids
AT vohlmarieclaude clinicalpracticeguidelinesusinggradeandagreeiifortheimpactofgeneticvariantsonplasmalipidlipoproteinapolipoproteinresponsivenesstoomega3fattyacids